Literature DB >> 6994782

Comparison of guanfacine and clonidine as antihypertensive agents.

A Jäättelä.   

Abstract

1. The antihypertensive effects and side-effects of guanfacine and clonidine were compared in a single-blind, cross-over study. 2. The study consisted of two active treatment periods of 6 weeks each, which were both preceded by a 2 weeks placebo period. Thirty ambulatory, hypertensive patients (blood pressure WHO severity grades I-II) were admitted to the study. The results are based on the 24 patients who completed the study. 3. The optimal daily dose of guanfacine was in over half of the patients 3-4 mg, and of clonidine correspondingly 0.3-0.45 mg. A similar and statistically significant decrease in blood pressure was achieved with both drugs. 4. The most common side-effects with both drugs were tiredness and dryness of the mouth.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994782      PMCID: PMC1430100          DOI: 10.1111/j.1365-2125.1980.tb04908.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane.

Authors:  H Schmitt; S Fenard
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

2.  Clonidine hydrochloride in the treatment of hypertension.

Authors:  S W Hoobler; E Sagastume
Journal:  Am J Cardiol       Date:  1971-07       Impact factor: 2.778

3.  Effects of clonidine withdrawal: possible mechanisms and suggestions for management.

Authors:  S N Hunyor; L Hansson; T S Harrison; S W Hoobler
Journal:  Br Med J       Date:  1973-04-28

4.  Clonidine (Catapres): a new antihypertensive agent.

Authors:  A Khan; G Camel; H M Perry
Journal:  Curr Ther Res Clin Exp       Date:  1970-01
  4 in total
  1 in total

1.  Hypertensive Crisis in a Pediatric Patient Experiencing Clonidine Withdrawal.

Authors:  Can Cao; Matthew L Lorenz; Phillip Sojka; Allison W Brindle; Lisa Swartz Topor
Journal:  Case Rep Pediatr       Date:  2022-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.